LYMPHOMA, SMALL LYMPHOCYTIC
Clinical trials for LYMPHOMA, SMALL LYMPHOCYTIC explained in plain language.
Never miss a new study
Get alerted when new LYMPHOMA, SMALL LYMPHOCYTIC trials appear
Sign up with your email to follow new studies for LYMPHOMA, SMALL LYMPHOCYTIC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug pirtobrutinib tested for Long-Term safety in blood cancers
Disease control Recruiting nowThis study is checking the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already been treated with other drugs. About 150 adults who completed a previous pirtobrutinib study can join. They…
Matched conditions: LYMPHOMA, SMALL LYMPHOCYTIC
Phase: PHASE4 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug combo aims to outperform standard therapy for Hard-to-Treat blood cancers
Disease control Recruiting nowThis phase 3 trial is testing whether a new drug, nemtabrutinib, combined with venetoclax works better than the current standard of venetoclax plus rituximab for people with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 735 p…
Matched conditions: LYMPHOMA, SMALL LYMPHOCYTIC
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Immune cell therapy takes on tough blood cancers
Disease control Recruiting nowThis study tests a treatment called JCAR017, a type of CAR T-cell therapy, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, which are modi…
Matched conditions: LYMPHOMA, SMALL LYMPHOCYTIC
Phase: PHASE1, PHASE2 • Sponsor: Juno Therapeutics, a Subsidiary of Celgene • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
CAR-T cell patients monitored for 15 years in new study
Knowledge-focused Recruiting nowThis study follows 500 people who received CAR-T cells in earlier trials for blood cancers like lymphoma and multiple myeloma. Researchers will check for new cancers and track long-term safety and effectiveness over 15 years. No new treatment is given; it is purely an observation…
Matched conditions: LYMPHOMA, SMALL LYMPHOCYTIC
Sponsor: Medical College of Wisconsin • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC